Nivolumab for Resected Stage III or IV Melanoma at 9 Years

Journal:
The New England Journal of Medicine
Published:
DOI:
10.1056/nejmoa2504966
Affiliations:
34
Authors:
29
Go to article
Institutions Authors Share
Bristol-Myers Squibb, United States of America (USA)
5.000000
 0.17
Tasman Health Care, Australia
1.000000
 0.03
Hospital Timone, France
1.000000
 0.03
IRCCS Istituto Oncologico Veneto (IOV), Italy
1.000000
 0.03
Princess Margaret Cancer Centre, U of T, Canada
1.000000
 0.03
National and Kapodistrian University of Athens (UOA), Greece
1.000000
 0.03
Siena University Hospital, Italy
1.000000
 0.03
IRCCS European Institute of Oncology (IEO), Italy
1.000000
 0.03
Lyon University Hospital (HCL), France
1.000000
 0.03
The Royal Marsden Hospital - London, The Royal Marsden NHS Foundation Trust, United Kingdom (UK)
1.000000
 0.03
Mount Sinai Medical Center (MSMC), United States of America (USA)
1.000000
 0.03
Gregorio Marañon University Hospital, Spain
1.000000
 0.03
IRCCS Istituto Nazionale Tumori IRCCS-Fondazione G. Pascale, Italy
1.000000
 0.03
Mount Vernon Cancer Centre, United Kingdom (UK)
1.000000
 0.03
H. Lee Moffitt Cancer Center & Research Institute, United States of America (USA)
1.000000
 0.03
University of Michigan Rogel Cancer Center, United States of America (USA)
1.000000
 0.03
August Pi i Sunyer Biomedical Research Institute (IDIBAPS), Spain
1.000000
 0.03
Azienda Ospedaliera Papa Giovanni XXIII, Italy
1.000000
 0.03
IRCCS National Cancer Institute (INT) Milan, Italy
1.000000
 0.03
Sir Charles Gairdner Hospital (SCGH), Australia
0.500000
 0.02
Centrul de Oncologie Sf Nectarie Craiova, Romania
0.500000
 0.02
The University of Western Australia (UWA), Australia
0.500000
 0.02
University Hospital Královské Vinohrady, Czech Republic
0.500000
 0.02
University of Medicine and Pharmacy Craiova (UMF Craiova), Romania
0.500000
 0.02
Texas Oncology, United States of America (USA)
0.500000
 0.02
Baylor Scott & White Health, United States of America (USA)
0.500000
 0.02
Charles University (CU), Czech Republic
0.500000
 0.02
Institute of Biomedicine of Seville (IBiS), Spain
0.333333
 0.01
Hospital Universitario Virgen Macarena, Spain
0.333333
 0.01
Princess Alexandra Hospital, Australia
0.333333
 0.01
The University of Queensland (UQ), Australia
0.333333
 0.01
University of Seville (US), Spain
0.333333
 0.01
Gallipoli Medical Research Foundation, Australia
0.333333
 0.01
Interested in Oncology and Carcinogenesis?